BPC-157 Dosage Guide: Injectable and Oral Protocols by Injury Type

Body Protection Compound-157 (BPC-157) is a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice. Dosing ranges from 200 to 1,000 mcg daily depending on your delivery method, injury type, and treatment goals — but most protocols cluster between 250 and 500 mcg. The evidence behind those numbers is primarily preclinical: only three published human studies exist as of early 2026, involving fewer than 30 total subjects. What you use, how you inject it, and how long you run it matters more than landing on a precise microgram count.

Key takeaways

BPC-157 dosage ranges from 200–1,000 mcg daily, with 250–500 mcg being the most commonly used range across all delivery methods
Subcutaneous injection (250–500 mcg daily) works best for systemic recovery and gut support; intramuscular injection (500 mcg near the injury site) targets localized tendon and ligament repair
Oral BPC-157 (250–500 mcg, 1–2 times daily on an empty stomach) is preferred for gastrointestinal conditions like leaky gut, IBS, and ulcers — oral delivery has lower systemic bioavailability for musculoskeletal healing
Cycle length scales with injury severity: 2–4 weeks for mild strains, 4–6 weeks for moderate tears, 6–8 weeks for post-surgical or chronic conditions
BPC-157 is a research peptide with no FDA approval for human use; work with a licensed physician before starting any protocol

PeptideRx rates the evidence for BPC-157 dosing protocols as Grade C, reflecting primarily animal and in vitro data with limited human clinical evidence (3 published studies, fewer than 30 total subjects as of early 2026).

Before you start BPC-157 is not FDA-approved for any human therapeutic use. All dosing protocols described here reflect preclinical research (primarily animal studies) and practitioner-reported clinical experience — not prescribing recommendations. Consult a licensed physician before starting any peptide protocol, particularly for post-surgical recovery, severe injuries, or chronic conditions.

Understanding BPC-157 dosage units

BPC-157 is measured in micrograms (mcg), not milligrams (mg). One milligram equals 1,000 micrograms. A standard 500 mcg dose equals just 0.5 mg.

Precision matters at this scale. An insulin syringe with unit markings enables accurate mcg-level measurement after reconstitution. Here is how the math works with common vial sizes:

5 mg vial + 2 ml bacteriostatic water:

Concentration: 2,500 mcg/ml (2.5 mg/ml)
0.1 ml drawn = 250 mcg
0.2 ml drawn = 500 mcg

2 mg vial + 2 ml bacteriostatic water:

Concentration: 1,000 mcg/ml (1 mg/ml)
0.25 ml drawn = 250 mcg
0.5 ml drawn = 500 mcg

Always calculate your concentration before drawing your dose. A labeling mistake at the vial level compounds into every injection.

Learn more about BPC-157: full profile, mechanism, and evidence review.

Delivery methods: subcutaneous, intramuscular, and oral

Your delivery method determines where BPC-157 goes in your body and which conditions it targets most effectively. No single method is better across the board — the right choice depends on what you are trying to heal.

Attribute	Subcutaneous (SubQ)	Intramuscular (IM)	Oral
Dose range	250–500 mcg	500 mcg	250–500 mcg
Frequency	Once daily	Once daily	1–2 times daily
Needle gauge	29–31 gauge insulin syringe	27–30 gauge, 1-inch needle	N/A
Injection depth	1/4–1/2 inch under the skin	1 inch into muscle tissue	N/A
Best for	Systemic recovery, gut support, general soreness	Localized tendon, ligament, and joint repair	GI conditions (leaky gut, IBS, ulcers)
Bioavailability	Good systemic distribution	Highest concentration at injury site	Lower systemic absorption; direct gut lining contact

Subcutaneous injection

SubQ is the most common delivery method for BPC-157. The peptide enters the fatty tissue just beneath the skin and passes into systemic circulation.

Step-by-step SubQ technique:

Draw 250–500 mcg of reconstituted BPC-157 into a 29–31 gauge insulin syringe
Clean the injection site with an alcohol swab
Pinch a fold of skin at the abdomen (2 inches from the navel) or upper outer thigh
Insert the needle at a 45-degree angle into the skin fold
Inject slowly over 3–5 seconds, hold for 2 seconds, then withdraw
Rotate injection sites daily to prevent scar tissue buildup

SubQ suits patients seeking systemic healing, gut support, or recovery from general muscle soreness. The technique is straightforward and can be self-administered after training from a healthcare provider.

Intramuscular injection

IM injection delivers BPC-157 directly into muscle tissue near the injury site, creating the highest local peptide concentration at the point of damage. This may enhance localized angiogenesis (new blood vessel formation) and collagen synthesis.

Step-by-step IM technique:

Draw 500 mcg of reconstituted BPC-157 into a 27–30 gauge, 1-inch needle syringe
Clean the injection site with an alcohol swab
Inject at a 90-degree angle perpendicular to the muscle, within 2–3 inches of the injury site
Aspirate briefly (pull the plunger back) to confirm you have not entered a blood vessel
Inject slowly, then apply light pressure post-injection

Standard IM sites include the deltoid (shoulder), vastus lateralis (outer thigh), and gluteus. For targeted healing, inject as close to the injured tendon, ligament, or joint as safely possible. IM injection is a more advanced technique — initial guidance from a healthcare provider is strongly recommended.

Oral administration

Oral BPC-157 is the preferred method for gastrointestinal conditions. BPC-157 is unusually stable in gastric acid, surviving the digestive environment better than most peptides. Oral delivery places the peptide in direct contact with the gut lining, making it appropriate for leaky gut, IBS, Crohn’s disease, ulcerative colitis, and peptic ulcers.

Standard oral dosing: 250–500 mcg, 1–2 times daily on an empty stomach (30–60 minutes before meals). Splitting doses between morning and evening provides more consistent gut coverage for GI protocols.

Oral BPC-157 has lower systemic bioavailability for musculoskeletal healing compared to injectable forms. Oral delivery is not a substitute for injectable protocols when treating tendon, ligament, or muscle injuries.

Learn more about peptides for gut health: what the research shows.

How to reconstitute injectable BPC-157

BPC-157 ships as a lyophilized (freeze-dried) powder that must be reconstituted before injection. Most dosing guides skip this step. Here is the full process.

What you need:

BPC-157 vial (typically 2 mg or 5 mg)
Bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative)
Sterile syringe for mixing (separate from your injection syringe)
Alcohol swabs
Insulin syringe for dose administration (29–31 gauge)

Step-by-step reconstitution:

Wipe the tops of both vials with alcohol swabs
Draw your chosen volume of bacteriostatic water into the sterile mixing syringe (2 ml is standard)
Insert the needle into the BPC-157 vial and inject the water slowly down the inside wall — do not inject directly onto the powder
Swirl the vial gently until the powder fully dissolves — never shake the vial; shaking can break peptide bonds and reduce potency
Refrigerate the reconstituted vial immediately at 36–46°F (2–8°C)
Label the vial with the date and concentration

Storage rules:

Reconstituted BPC-157 stays viable for 2–4 weeks when refrigerated with bacteriostatic water
Bacteriostatic water’s benzyl alcohol content prevents bacterial growth in multi-use vials
Discard after 4 weeks, or sooner if the solution becomes cloudy or discolored
Never freeze reconstituted peptide solution

BPC-157 dosage by injury type

Key takeaways

Tendon and ligament injuries use IM injection at 500 mcg daily near the injury site; a 2025 systematic review (Vasireddi et al., PMID: 40756949) confirmed improved functional and structural outcomes across 36 preclinical studies
One published human study (Lee & Padgett, 2021) reported symptom relief lasting 6+ months in 7 of 12 chronic knee pain patients after intra-articular BPC-157 injection
GI conditions use oral delivery at 250–500 mcg twice daily on an empty stomach; BPC-157’s unusual acid stability makes oral delivery viable for gut applications
Post-surgical protocols use the higher dose range (500–750 mcg daily) and require direct medical supervision

Injury type and severity determine your dose, delivery method, and cycle length. Your prescribing physician should adjust all protocols to your specific situation.

Injury/condition	Dose	Frequency	Method	Cycle length
Tendon injury (rotator cuff, Achilles, patellar)	500 mcg	Once daily	IM near injury	4–6 weeks (moderate); 6–8 weeks (severe)
Ligament tear (ACL, MCL, ankle)	500 mcg	Once daily	IM near injury	4–6 weeks (partial); 6–8 weeks (complete)
Muscle strain/tear	250–500 mcg	Once daily	SubQ or IM	2–4 weeks (mild); 4–6 weeks (significant)
Post-surgical recovery	500–750 mcg	Once daily	IM or SubQ	6–8 weeks
GI conditions (leaky gut, IBS, ulcers, Crohn’s)	250–500 mcg	1–2 times daily	Oral	4–6 weeks

Tendon and ligament injuries

Tendon and ligament healing relies on collagen synthesis and new blood vessel formation at the injury site. Preclinical research from Sikiric et al. consistently demonstrates that BPC-157 enhances fibroblast activity (the cells that produce collagen) and upregulates VEGFR2 expression (a receptor involved in blood vessel growth) in animal models of tendon and ligament damage.

IM injection near the injury site at 500 mcg daily is the standard protocol. A 2025 systematic review (Vasireddi et al., HSS Journal, PMID: 40756949) analyzed 36 studies and confirmed that BPC-157 improved functional, structural, and biomechanical outcomes across preclinical tendon, ligament, muscle, and bone injury models.

One published human study (Lee & Padgett, 2021, Alternative Therapies in Health and Medicine) reported that 7 of 12 patients with chronic knee pain experienced symptom relief lasting over 6 months after intra-articular BPC-157 injection. That study used approximately 4,000 mcg per injection — significantly above standard subcutaneous dosing — highlighting that human protocols are still exploratory.

GI conditions

BPC-157 originated from research into gastric mucosal protection. The peptide reached Phase II clinical trials for ulcerative colitis, though results were limited. Preclinical studies demonstrate protection against NSAID-induced gastropathy, ethanol-induced gastric lesions, and inflammatory bowel models.

Oral dosing at 250–500 mcg twice daily on an empty stomach is the standard GI protocol. BPC-157’s resistance to gastric acid degradation makes oral delivery viable for gut applications — unlike most peptides, which break down in the stomach before reaching the intestine.

Post-surgical recovery

Post-surgical protocols use the higher end of the dosing range (500–750 mcg daily) for 6–8 weeks. Doses above 500 mcg require direct medical supervision. The delivery method (IM vs. SubQ) depends on the surgery site and your physician’s judgment.

Learn more about peptides for injury recovery: what the research shows.

Cycle length: how long to run your protocol

Cycle length matches injury severity. BPC-157 has a half-life of less than 30 minutes (based on pharmacokinetic data from Vasireddi et al., 2025), so no loading phase is needed. Consistent daily dosing builds the cumulative signaling your cells need to repair tissue.

Mild injuries (2–4 weeks)

Minor muscle strains, mild tendinopathy, and small soft tissue tears respond within the shortest cycle window. Healing signals activate within 7–10 days. Complete tissue repair for mild injuries typically finishes by week 4 at 250–500 mcg daily.

Moderate injuries (4–6 weeks)

Partial ligament tears, moderate tendon damage, and recovery from minor surgical procedures require the middle cycle window. Structural collagen remodeling takes longer than initial pain relief — feeling significantly better by week 2 does not mean the tissue has finished rebuilding. Completing the full 4–6 week cycle reduces re-injury risk.

Severe and chronic conditions (6–8+ weeks)

Complete ligament tears (post-surgical), major tendon repairs, and chronic inflammatory conditions require extended protocols. Some chronic inflammation cases run 8–12 weeks under physician supervision. Post-surgical patients benefit from starting BPC-157 as soon as their physician clears them for peptide therapy.

Tapering and breaks

Tapering is optional. BPC-157 can be stopped without rebound effects. Many practitioners recommend a 2–4 week break between cycles to assess whether tissue repair is structural (lasting) rather than just symptomatic.

Dosing frequency and timing

Injectable BPC-157 (SubQ or IM): Once daily is standard. Timing is flexible — morning, midday, or evening all work. No circadian advantage exists for one window over another. Consistency matters more than clock time.

Oral BPC-157: Take on an empty stomach, 30–60 minutes before meals. For twice-daily GI protocols, split doses between morning and evening (for example, 250 mcg before breakfast and 250 mcg before dinner).

Twice-daily injectable protocols exist for severe injuries but offer marginal benefit over once-daily dosing for most users. The added injection creates unnecessary complexity without clear evidence of better outcomes.

Stacking BPC-157 with other peptides

The BPC-157 + TB-500 stack

The most widely used peptide stack for injury recovery combines BPC-157 with TB-500 (Thymosin Beta-4). The two peptides work through different but complementary mechanisms.

BPC-157 targets localized tissue repair — stimulating collagen synthesis, fibroblast activation, and new blood vessel formation via VEGFR2 and eNOS pathways at the injury site.

TB-500 provides systemic healing support — promoting cell migration toward injury sites, regulating actin (a protein involved in cell structure and movement), and reducing systemic inflammation.

Compound	Dose	Frequency	Method
BPC-157	250–500 mcg	Once daily	SubQ or IM
TB-500	2–5 mg/week	Split into 2–3 injections	SubQ

Standard cycle: 6–8 weeks. TB-500 is often tapered to once weekly after the first 4 weeks while BPC-157 continues daily. No dose reduction is needed for either compound when stacking.

No controlled human trial has studied the BPC-157 + TB-500 combination. Both remain research peptides without FDA approval. Medical supervision is recommended for any multi-peptide protocol.

Growth hormone peptide stack

Some practitioners add CJC-1295 (100–200 mcg) and Ipamorelin (100–200 mcg) to BPC-157 protocols for enhanced recovery support. Growth hormone peptides complement BPC-157’s direct tissue repair with broader metabolic and anabolic recovery benefits. Maintain the full BPC-157 dose when adding GH peptides.

Learn more about TB-500: mechanism, evidence, and injury recovery protocols.

Does body weight affect BPC-157 dosage?

No. BPC-157 dosing does not scale with body weight. A 150-pound person and a 250-pound person use the same 250–500 mcg dose range. This differs from many pharmaceutical compounds where dose adjusts per kilogram of body mass.

BPC-157 works through localized tissue signaling — angiogenesis, fibroblast activation, growth factor expression — rather than concentration-dependent systemic pathways. Preclinical research demonstrates comparable healing outcomes across a wide range of animal body weights when BPC-157 is dosed by injury severity.

Three factors determine your dose: injury severity (mild injuries use the lower range; severe injuries use the higher range), injury type (tendon/ligament injuries favor IM; GI conditions favor oral), and delivery method (SubQ for systemic, IM for localized, oral for gut).

Safety and side effects

Common side effects (generally mild)

Side effect	Notes
Injection site redness or irritation	Most common; resolves within 24–48 hours
Temporary tingling at the injection site	Mild; transient
Transient headache	Rare
Mild nausea	Primarily with oral dosing

Serious adverse events have not been reported in published human studies. A 2025 IV safety pilot (Lee & Burgess, Alternative Therapies in Health and Medicine, PMID: 40131143) administered 10–20 mg of BPC-157 intravenously to 2 healthy adults with no adverse effects on cardiac, hepatic, renal, thyroid, or metabolic function.

Preclinical safety data

The 2025 systematic review (Vasireddi et al., HSS Journal) summarized preclinical safety findings across three studies:

No acute toxicity across multiple organ systems after single and repeated IM and IV doses ranging from 6 mcg/kg to 20 mg/kg over 6 weeks in rat and dog models
No microscopic tissue changes in the liver, spleen, lung, kidney, brain, thymus, prostate, or ovaries
No mutagenic or genotoxic effects (negative Ames test; no chromosomal aberrations)
No teratogenic effects when administered during pregnancy in rat models
No established lethal dose (LD50) at any tested dosage

Important: These are animal findings. Human safety data is extremely limited (3 studies, fewer than 30 subjects). The favorable preclinical profile is encouraging but does not substitute for long-term human safety evidence.

Dosage ceiling

The practical daily maximum is 1,000 mcg. Standard protocols stay within 200–750 mcg. Doses above 750 mcg daily require physician oversight.

Contraindications

Active cancer: BPC-157 promotes angiogenesis (new blood vessel growth). Angiogenesis can theoretically support tumor growth. Anyone with active cancer or a cancer history should consult an oncologist before considering BPC-157.

Pregnancy and breastfeeding: Insufficient safety data. Not recommended.

Peptide sensitivity: Rare but possible. Discontinue immediately if you develop severe rash, swelling, or difficulty breathing.

Common dosing mistakes

Shaking the vial during reconstitution. Shaking can break peptide bonds and reduce potency. Always swirl gently until the powder dissolves.

Using sterile water instead of bacteriostatic water. Plain sterile water lacks the preservative (benzyl alcohol) that prevents bacterial growth. Without it, the reconstituted vial must be used within 24 hours.

Skipping days. BPC-157’s half-life is less than 30 minutes. Tissue repair requires sustained daily signaling. Missed doses break the angiogenesis and collagen synthesis cascade and delay healing.

Using oral delivery for musculoskeletal injuries. Oral BPC-157 has lower systemic bioavailability. Taking oral capsules for a torn rotator cuff will not produce the same results as IM injection near the shoulder.

Stopping too early. Feeling better at day 10 does not mean the tissue has fully healed. Structural collagen remodeling requires the full 4–6+ week cycle. Premature termination increases re-injury risk.

Learn more about peptide side effects: what the clinical research actually shows.

Legal status (2026)

BPC-157 is not FDA-approved for human use. The FDA classified BPC-157 as a Category 2 bulk drug substance in late 2023, restricting licensed compounding pharmacies from preparing it for patients.

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 Category 2 peptides — BPC-157 included — would be reclassified back to Category 1. As of March 2026, the FDA has not published the formal updated Category list. The announcement signals regulatory intent, but formal reclassification has not been finalized.

What this means for you:

BPC-157 remains a research compound with no FDA approval for any therapeutic indication
Category 1 status (if formalized) would allow licensed 503A and 503B compounding pharmacies to prepare BPC-157 under a valid physician’s prescription
Category 1 is not the same as FDA approval; no large-scale human clinical trials have been completed
Compounded peptides from licensed pharmacies carry substantially better quality assurance than grey-market “research use only” products

Always work with a licensed physician — sports medicine, orthopedics, or a provider experienced with peptide therapy — before starting any BPC-157 protocol.

Learn more about FDA peptide reclassification 2026: what the announcement means.

The bottom line

BPC-157 dosage protocols center on three delivery methods and scale with injury severity. Subcutaneous injection at 250–500 mcg daily suits systemic recovery; intramuscular injection at 500 mcg near the injury targets localized tendon and ligament repair; oral dosing at 250–500 mcg twice daily addresses gastrointestinal conditions. Cycle length runs 2–4 weeks for mild injuries up to 6–8 weeks for severe or post-surgical cases. Dosing is weight-independent — injury type and severity drive the protocol, not body mass. The honest caveat: the evidence base is almost entirely preclinical, with only three published human studies and fewer than 30 total subjects. Proper reconstitution, daily consistency, and completing the full cycle matter more than optimizing the exact mcg number. Work with a licensed physician, particularly for post-surgical recovery, severe injuries, and any multi-peptide stack.

Frequently asked questions

Does BPC-157 dosage depend on body weight?

No. BPC-157 dosing is weight-independent. Standard 250–500 mcg doses produce comparable results across individuals ranging from 150 to 250 lbs. Injury severity, injury type, and delivery method determine the dose — not body mass.

What is the maximum safe BPC-157 dosage?

The practical daily ceiling is 1,000 mcg. Most protocols stay within 200–750 mcg. Animal studies show no acute toxicity even at high doses (up to 20 mg/kg over 6 weeks), and no lethal dose has been established in preclinical research. A 2025 IV safety pilot (PMID: 40131143) tested 10,000–20,000 mcg intravenously in 2 adults with no adverse effects. Doses above 750 mcg daily should involve physician supervision.

Can I use oral BPC-157 instead of injectable for tendon injuries?

No — or at least, not as a direct substitute. Oral BPC-157 has lower systemic bioavailability for musculoskeletal healing compared to injectable delivery. Oral administration is best for GI conditions where direct gut lining contact is the mechanism. For tendon, ligament, or muscle injuries, subcutaneous or intramuscular injection delivers higher tissue-level concentrations at the injury site.

Does it matter what time of day I dose BPC-157?

For injectable BPC-157, timing is flexible. Morning, midday, or evening all work; consistency matters more than the specific hour. For oral BPC-157, take on an empty stomach 30–60 minutes before meals. For twice-daily GI protocols, split doses between AM and PM.

How long should I run a BPC-157 cycle?

Match cycle length to injury severity. Mild injuries (minor strains, mild tendinopathy): 2–4 weeks. Moderate injuries (partial tears, moderate tendon damage): 4–6 weeks. Severe injuries (complete tears, post-surgical, chronic conditions): 6–8 weeks. Some chronic inflammation cases extend to 8–12 weeks under medical supervision.

Is there clinical evidence for BPC-157 dosing in humans?

Limited. Only three published human studies exist as of early 2026, with fewer than 30 total subjects and no randomized controlled trials. Most dosing evidence comes from extensive preclinical animal research (Sikiric et al., 1993–2024) and practitioner-reported protocols. A 2025 systematic review (Vasireddi et al., HSS Journal, PMID: 40756949) screened 544 articles and found 35 preclinical studies and 1 clinical study supporting BPC-157’s healing mechanisms. Dosing protocols reflect this preclinical foundation combined with clinical experience, not established human trial data.

Considering BPC-157 for an injury or GI condition? Speak with a licensed physician experienced with peptide therapy to determine whether it fits your situation and to design a protocol matched to your specific needs.

References

Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. doi: 10.1177/15563316251355551. PMID: 40756949
Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med.2021;27. PMID: 36006598
Lee E, Burgess K. Safety of intravenous infusion of BPC-157 in humans: a pilot study. Altern Ther Health Med.2025;31(5):20-24. PMID: 40131143
Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30:12-17
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Pharmaceuticals (Basel). 2024;17(4):461. PMC: 11053547
McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025. PMID: 40789979
FDA. Certain bulk drug substances for use in compounding may present significant safety risks. FDA.gov. Updated 2024

Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. BPC-157 is not FDA-approved for any human therapeutic use and is classified as a research compound. Dosing ranges described in this guide reflect preclinical research (primarily animal models) and practitioner-reported clinical protocols — they are not prescribing recommendations.

Always consult a licensed physician before starting any peptide therapy. PeptideRx does not sell peptides or provide medical consultations. Content is reviewed by a licensed medical professional. For the most current FDA regulatory status of BPC-157, visit FDA.gov.

PeptideRx rates the evidence for BPC-157 dosing protocols as Grade C, reflecting primarily animal/in vitro data with limited human clinical evidence (3 published studies, fewer than 30 total subjects as of early 2026).